1L Nsclc Non Squamous DX All Comer Abraxane
Research payments
$4,196,725
Through program year 2022, $4,196,725 in research payments was reported against 1L Nsclc Non Squamous DX All Comer Abraxane, across 595 payments, paid by F. Hoffmann-La Roche AG.
- Paid by
- F. Hoffmann-La Roche AG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $277,864 | 5 |
| 2021 | Research | $1,362,899 | 136 |
| 2020 | Research | $820,181 | 168 |
| 2019 | Research | $1,735,781 | 286 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jennifer Suga Vallejo, CA Named on 76 payments
- Sonia Seng Fall River, MA Named on 26 payments
- Gregory Gerstner Peoria, IL Named on 25 payments
- Krishna Rao Springfield, IL Named on 20 payments
- Krishna Gunturu Burlington, MA Named on 17 payments
- Joshua Sabari New York, NY Named on 17 payments
- Tarek Mekhail Orlando, FL Named on 17 payments
- Mark Johns Cincinnati, OH Named on 16 payments
- Maen Hussein Leesburg, FL Named on 15 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.